Abstracts tagged "Lupus"

Abstract Number: 1111 • 2019 ACR/ARP Annual Meeting
Lupus Teledematology: A Pilot Project to Evaluate the Plausibility of a Rapid Access Dermatology Service for Lupus Patients
Richard Antbring¹, Malvina Cunningham ², Richard Bull ², Angela Pakozdi ¹, Ravindra Rajakariar ¹, Myles Lewis ¹, Andrea Cove-Smith ¹ and Debasish Pyne ³, ¹Barts Health Lupus Centre, London, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom, ³Barts Lupus Centre, London, United Kingdom
Background/Purpose: Clinicians have been increasingly using social media sites professionally. Platforms such as WhatsApp ® could be a potentially effective tool in teledermatology for rapid diagnosis and/or…
Abstract Number: 1626 • 2019 ACR/ARP Annual Meeting
Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus
Mario Cesar Ocampo Torres ¹, Elizabeth Olivares-Martinez ² and Juanita Romero-Diaz³, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico
Background/Purpose: Background/purpose Premature atherosclerosis has been recognized as a major cause of morbidity and mortality in SLE patients. We aimed to determine 1) the incidence…
Abstract Number: 2571 • 2019 ACR/ARP Annual Meeting
Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus
Zahi Touma¹, Dafna Gladman ², Shawn Rose ³, Kaiyin Fei ³, Yun Gregan ³, Robert Gordon ³, Kim Hung Lo ³ and Murray Urowitz ¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: While traditional Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI-2K) scoring assesses complete SLE response for individual disease manifestations, the SLEDAI-2K Responder Index-50…
Abstract Number: 666 • 2019 ACR/ARP Annual Meeting
Sensitivity to Change of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
William Fung¹, Mitra Moazzami ², Lisa Engel ³, Jiandong Su ⁴, Dennisse Bonilla ⁴, Pooneh Akhavan ⁵, Patricia Katz ⁶, Dorcas Beaton ⁷ and Zahi Touma ⁸, ¹University of Toronto, Toronto, ON, Canada, ²George Washington University, Washington, DC, ³University of Manitoba, Winnipeg, MB, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, Canada, ⁶University of California, San Francisco, san francisco, CA, ⁷St. Michael's Hospital, Toronto, ON, Canada, ⁸University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Patient-reported outcomes (PROs) measures are a key component of the care of patients with systemic lupus erythematosus (SLE). The Patient Reported Outcomes Measurement Information…
Abstract Number: 1124 • 2019 ACR/ARP Annual Meeting
The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Jennifer Lofland¹, Pamela Berry ², Feng Pan ², Chetan Karyekar ³, Hannah Guiang ⁴, Rebecca McTavish ⁴ and Melissa Thompson ⁴, ¹Janssen Scientific Affairs, LLC, Spring House, PA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Global Services, LLC, Horsham, PA, ⁴Cornerstone Research Group, Inc, Burlington, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. SLE tends to peak during prime working years, resulting in a high economic burden due…
Abstract Number: 1729 • 2019 ACR/ARP Annual Meeting
Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India
Sumidha Mittal ¹, Manjari Agarwal ¹ and Sujata Sawhney¹, ¹Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India
Background/Purpose: Children with systemic lupus erythematosus(cSLE) have more severe disease as compared to adults. Additionally, Asians in their geographic area have high burden of infections…
Abstract Number: 2576 • 2019 ACR/ARP Annual Meeting
Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE
Matthew Linnik¹, Adam Godzik ², Lukasz Jaroszewski ², Carl Ware ² and Andrew Vendel ¹, ¹Lilly Biotechnology Center, San Diego, CA, ²Sanford Burnham Prebys Medical Research Institute, La Jolla, CA
Background/Purpose: Background/Purpose: Immune checkpoint inhibitors have demonstrated durable benefit in some cancer patients. However, checkpoint inhibitors are also associated with new onset autoimmune adverse events. …
Abstract Number: 676 • 2019 ACR/ARP Annual Meeting
Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments
Zahi Touma¹, Benjamin Hoskin ², Christian Atkinson ², David Bell ², Olivia Massey ³, Jennifer Lofland ⁴, Pamela Berry ⁵, Chetan Karyekar ⁶ and Karen Costenbader ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Adelphi Real World, Cheshire, United Kingdom, ³Adelphi Real World, Bollington, United Kingdom, ⁴Janssen Scientific Affairs, LLC, Spring House, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, ⁶Janssen Global Services, LLC, Horsham, PA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous systemic lupus erythematosus (SLE) studies have identified potential clusters of SLE clinical manifestations. To describe the presentation of SLE across different cohorts of patients…
Abstract Number: 1185 • 2019 ACR/ARP Annual Meeting
New Imaging Modality to Evaluate Arthritis in Lupus Based on Frequency-domain Optical Transmission
Anca Askanase¹, Fiamma Van Biema ², Alessandro Marone ², Youngwan Kim ², Tommy Chen ², Teja Kapoor ², Laura Geraldino ², Yevgeniya Gartshteyn ³ and Andreas Hielscher ², ¹Columbia University Medical Center, New York, NY, ²Columbia University School of Medicine, New York, NY, ³Columbia University School of Medicine, Glen Rock, NJ
Background/Purpose: 95% of the people with SLE experience joint pain, stiffness and swelling at some time during their illness. It is currently difficult to both…
Abstract Number: 1730 • 2019 ACR/ARP Annual Meeting
Impact of Preceding and Co-existing Autoimmune Cytopenias on Severity of Childhood-onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study
Ekemini Ogbu¹, Shanmuganathan Chandrakasan ¹, Kelly Rouster-Stevens ¹, Larry Greenbaum ¹, Chelsea Marion ², Karli Singer ³, Iñaki Sanz ³ and Sampath Prahalad ¹, ¹Emory University and Children's Healthcare of Atlanta, ATLANTA, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Emory University, Atlanta, GA
Background/Purpose: Autoimmune cytopenias may precede or occur with childhood-onset systemic lupus erythematosus (cSLE). Adult studies suggest that lupus patients with concurrent autoimmune cytopenias have relatively…
Abstract Number: 2580 • 2019 ACR/ARP Annual Meeting
Pharmacotherapies Targeting Type 2 SLE Symptoms
Raeann Whitney¹, Amanda Eudy ¹, Megan Clowse ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, David Pisetsky ², Kai Sun ¹, Rebecca Sadun ¹ and Jennifer Rogers ¹, ¹Duke University, Durham, ²Duke University, Durham VAMC, Durham
Background/Purpose: We propose categorizing lupus activity to better align with patient experience: Type 1 SLE activity includes classic symptoms such as arthritis and nephritis; Type…
Abstract Number: 689 • 2019 ACR/ARP Annual Meeting
Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus
Alberta Hoi ¹, Hieu Nim ², Rachel Koelmeyer ², Ying Sun ³, Amy Kao ⁴, Oliver Guenther ³ and Eric Morand², ¹School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Merck Healthcare KGaA, Darmstadt, Germany, ⁴EMD Serono Research & Development Institute, Inc., Billerica, MA
Background/Purpose: High Disease Activity Status (HDAS), defined as ever attainment of SLEDAI-2k of 10 or greater, may be a useful indicator of overall disease severity in…
Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting
Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus
Nancy Desai¹, Hanni Menn-Josephy ¹, Ramon Bonegio ¹, Christina Lam ¹, Anna Kancharla ¹ and Michael York ¹, ¹Boston Medical Center, Boston
Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…
Abstract Number: 1734 • 2019 ACR/ARP Annual Meeting
Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients
Anastasia-vasiliki Madenidou¹, Yasmin Mahfouz ², Oliver Cheng ², Farah El-Sharnouby ², Charlene Foley ² and Coziana Ciurtin ³, ¹Centre for Adolescent Rheumatology, University College London London, UK, LOndon, ²Centre for Adolescent Rheumatology, University College London London, UK, London, United Kingdom, ³Centre for Adolescent Rheumatology, University College London London, UK, Londond, United Kingdom
Background/Purpose: An estimated 10-20% of all patients with systemic lupus erythematosus (SLE) develop clinical disease before the age of 18 years and are therefore classified…
Abstract Number: 2584 • 2019 ACR/ARP Annual Meeting
Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review
Jessica Fairley¹, Shereen Oon ², Amanda Saracino ³ and Mandana Nikpour ², ¹Monash University, Melbourne, Australia, ²St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia, ³University College London, London, United Kingdom
Background/Purpose: Cutaneous lupus erythematosus (CLE), occurring with or without systemic lupus erythematosus (SLE), is a group of inflammatory skin diseases that can be very debilitating,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].